Literature DB >> 7796441

Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog.

T Mizumura1, K Nithipatikom, G J Gross.   

Abstract

OBJECTIVE: The major aim of this study was to determine if nicorandil, a potassium channel opener nitrate, produces a reduction in myocardial infarct size at a non-hypotensive dose in dogs and to determine if this effect is the result of an increase in adenosine release or reduction in neutrophil infiltration into the ischaemic area. Glyceryl trinitrate was used for purposes of comparison.
METHODS: Barbitone anaesthetised dogs were subjected to 60 min of left anterior descending coronary artery occlusion followed by 3 h of reperfusion. Nicorandil (100 microgram.kg-1 bolus followed by a 10 microgram.kg-1.min-1 infusion; NC/pre group), glyceryl trinitrate (10 microgram.kg-1 bolus followed by a 1 microgram.kg-1.min-1 infusion; GTN/pre group), or an equivalent volume of saline (control group) were given intravenously 15 min before occlusion and continued to the time of reperfusion. In two other groups, nicorandil (NC/post group) or glyceryl trinitrate (GTN/post group) were given 10 min before reperfusion and continued until the end of the experiment. To measure the release of adenosine from the ischaemic region, coronary venous blood samples were collected before occlusion, during occlusion, and at various times following reperfusion. Myocardial infarct size was determined by triphenyltetrazolium chloride and transmural myocardial blood flow by radioactive microspheres. Transmural myeloperoxidase activity, an index of neutrophil infiltration, was measured in biopsies obtained from the area at risk.
RESULTS: Pretreatment with nicorandil and glyceryl trinitrate caused a marked reduction in myocardial infarct size expressed as percent of the area at risk [NC/pre group, 7.8(SEM 1.6)%; GTN/pre group, 11.9(2.3)%; control group, 31.0(5.6)%]. When nicorandil and glyceryl trinitrate were given before reperfusion, both drugs still produced a significant reduction in infarct size [NC/post group, 13.8(2.0)%; GTN/post group, 18.9(4.3)%]. Coronary venous adenosine concentrations during reperfusion were significantly lower in both nicorandil and glyceryl trinitrate pretreated groups, but not in the post-treated groups. Transmural myeloperoxidase activity was significantly lower in both nicorandil treated groups.
CONCLUSIONS: Pretreatment with a non-hypotensive dose of nicorandil or glyceryl trinitrate markedly reduces myocardial infarct size and adenosine release from the ischaemic-reperfused area. These agents were also effective, but to a lesser degree, when given just before reperfusion. The cardioprotective actions of nicorandil appear to be related not only to its potassium channel opening activity but also in part to its nitrate activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796441

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  14 in total

Review 1.  ATP-sensitive potassium channels and myocardial preconditioning.

Authors:  G J Gross
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

Review 2.  Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements?

Authors:  G J Gross; D A Mei; J J Schultz; T Mizumura
Journal:  Basic Res Cardiol       Date:  1996 Jan-Feb       Impact factor: 17.165

3.  Effects of adding intravenous nicorandil to standard therapy on cardiac sympathetic nerve activity and myocyte dysfunction in patients with acute decompensated heart failure.

Authors:  Shu Kasama; Takuji Toyama; Ryuichi Funada; Noriaki Takama; Norimichi Koitabashi; Shuichi Ichikawa; Yasuyuki Suzuki; Naoya Matsumoto; Yuichi Sato; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-30       Impact factor: 9.236

4.  Nicorandil ameliorates posttransplant dysfunction in cardiac allografts harvested from non-heart-beating donors.

Authors:  Makoto Mohri; Kotaro Suehiro; Shu Yamamoto; Hiroki Yamaguchi; Kozo Ishino; Shunji Sano
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-10

5.  Nicorandil ameliorates ischaemia-reperfusion injury in the rat kidney.

Authors:  Shogo Shimizu; Motoaki Saito; Yukako Kinoshita; Fumiya Ohmasa; Fotios Dimitriadis; Kohei Shomori; Atsushi Hayashi; Keisuke Satoh
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

6.  Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits.

Authors:  Xian-Liang Tang; Yu-Ting Xuan; Yanqing Zhu; Gregg Shirk; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-12-18       Impact factor: 4.733

7.  Nicorandil attenuates the mitochondrial Ca2+ overload with accompanying depolarization of the mitochondrial membrane in the heart.

Authors:  Hideyuki Ishida; Naoko Higashijima; Yuki Hirota; Chokoh Genka; Hiroe Nakazawa; Haruaki Nakaya; Toshiaki Sato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-12-18       Impact factor: 3.000

8.  Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction.

Authors:  N Ikeda; T Yasu; N Kubo; S Hashimoto; Y Tsuruya; M Fujii; M Kawakami; M Saito
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

9.  Nicorandil protects cardiac mitochondria against permeability transition induced by ischemia-reperfusion.

Authors:  Raquel S Carreira; Pedro Monteiro; Alicia J Kowaltowski; Lino M Gonçalves; Luís A Providência
Journal:  J Bioenerg Biomembr       Date:  2008-04-16       Impact factor: 2.945

10.  Effects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: subanalysis of our previous report using propensity score matching.

Authors:  Shu Kasama; Takuji Toyama; Toshiya Iwasaki; Hiroyuki Sumino; Hisao Kumakura; Kazutomo Minami; Shuichi Ichikawa; Naoya Matsumoto; Yuichi Sato; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.